- Home
- HCWB
HCWB
HCW Biologics Inc.
as 06-02-2025 4:00pm EST
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | MIRAMAR |
| Market Cap: | 16.1M | IPO Year: | 2021 |
| Target Price: | $35.00 | AVG Volume (30 days): | 2.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -8.74 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.00 - $100.80 | Next Earning Date: | 05-15-2025 |
| Revenue: | $1,445,145 | Revenue Growth: | -63.20% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of HCW Biologics Inc. (HCWB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| GARRETT SCOTT T | HCWB | Director | May 16 '25 | Buy | $7.45 | 13,423 | $100,001.35 | 25,505 | |
| Winer Gary M | HCWB | Director | May 16 '25 | Buy | $7.45 | 1,342 | $9,997.90 | 4,075 | |
| Wong Hing C | HCWB | Chief Executive Officer | May 16 '25 | Buy | $7.45 | 8,054 | $60,002.30 | 501,911 | |
| GARRETT SCOTT T | HCWB | Director | May 7 '25 | Buy | $26.00 | 5,385 | $140,010.00 | 25,505 | |
| Greene Rick S. | HCWB | Director | May 7 '25 | Buy | $26.00 | 962 | $25,012.00 | 2,066 | |
| Flowers Lee | HCWB | SVP of Business Development | May 7 '25 | Buy | $26.00 | 962 | $25,012.00 | 5,720 | |
| Byam Rebecca | HCWB | Chief Financial Officer | May 7 '25 | Buy | $26.00 | 8,462 | $220,012.00 | 43,010 | |
| Wong Hing C | HCWB | Chief Executive Officer | May 7 '25 | Buy | $26.00 | 92,500 | $2,405,000.00 | 501,911 |
Latest HCW Biologics Inc. News
HCWB Breaking Stock News: Dive into HCWB Ticker-Specific Updates for Smart Investing
GlobeNewswire
18 days ago
HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results
MT Newswires
21 days ago
HCW Biologics Says Studies Show HCW9206 Fusion Protein Addresses Key Challenges for CAR-T Therapies; Shares Surge
GlobeNewswire
21 days ago
HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization
MT Newswires
24 days ago
Hcw Biologics Insider Bought Shares Worth $2,405,000, According to a Recent SEC Filing
MT Newswires
2 months ago
HCW Biologics to Implement 1-for-40 Reverse Stock Split
GlobeNewswire
2 months ago
HCW Biologics Announces 1-for-40 Reverse Stock Split
GlobeNewswire
2 months ago
HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results
GlobeNewswire
3 months ago
HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements
Compare HCWB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HCWB HCW Biologics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.